Xencor Inc

XE9

Company Profile

  • Business description

    Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.

  • Contact

    465 North Halstead Street
    Suite 200
    PasadenaCA91107
    USA

    T: +1 626 305-5900

    E: [email protected]

    https://www.xencor.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    260

Stocks News & Analysis

stocks

Weight loss drugs not an existential threat to undervalued ASX share

A durable growth story despite GLP-1 headwinds.
stocks

Tesla: valuation is key consideration in merger talks with SpaceX

We see regulatory risk from both the US and Chinese governments.
stocks

ASX data center shares remain cheap after downgrade

Near-term pain, long-term potential.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,926.6020.800.23%
CAC 407,847.3264.500.83%
DAX 4025,410.84229.190.91%
Dow JONES (US)52,364.02148.860.29%
FTSE 10010,767.3376.970.72%
HKSE23,211.81118.440.51%
NASDAQ26,169.38214.040.82%
Nikkei 22562,189.65503.51-0.80%
NZX 50 Index13,733.9312.91-0.09%
S&P 5007,676.8653.180.70%
S&P/ASX 2008,809.9014.700.17%
SSE Composite Index3,697.527.040.19%

Market Movers